Clinical Trial Update: Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe [Phase 1]

View source ↗

Summary

This Phase 1 study evaluated the reliability of dosing with NovoLog Mix 70/30 FlexPen compared with vial and syringe in people with Type 2 diabetes. The trial h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• NovoLog Mix 70/30 FlexPen (insulin aspart protamine/insulin aspart)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED